"Hidden Gem" unearthed: Zoom (ZM.US) investment in Anthropic yields nearly a hundredfold profit Baird reaffirms "outperforming the market" rating.
Analyst William Power of Baird reiterated his "outperform" rating on Zoom and maintained a target stock price of $95.
On Monday, the stock price of video conferencing company Zoom (ZM.US) surged more than 11%. Prior to this, investment firm Baird highlighted Zoom's investment in the emerging artificial intelligence (AI) startup Anthropic in its report.
Baird analyst William Power wrote in a research report to clients, "Although our and the market's previous focus was mainly on whether Zoom can gradually regain revenue growth momentum and seize the AI opportunity, the company's $51 million investment in Anthropic may be a 'hidden gem' that has not been fully appreciated." Power reiterated his "outperform" rating for Zoom and maintained a target price of $95.
It is understood that Zoom's venture capital department completed its investment in Anthropic in 2023, the latter being the developer of the popular Claude series AI models. Earlier this month, there were reports that Anthropic was in talks to raise $10 billion at a valuation of $350 billion. Baird stated that based on this valuation, Zoom's stake could be worth $2 billion to $4 billion.
The latest data shows that Anthropic's annualized revenue scale has recently exceeded $9 billion.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


